#United States #Karyopharm #XPOVIO #Newton #KPTI

Karyopharm Therapeutics Grants Restricted Stock Units

Karyopharm Therapeutics Inc., a leading player in the pharmaceutical industry specializing in innovative cancer treatments, has recently made a significant announcement concerning its employee compensation strategy. On December 2, 2024, the company revealed the issuance of a total of 4,800 restricted stock units (RSUs) to two newly hired employees. This move is part of the company's 2022 Inducement Stock Incentive Plan, and complies with Nasdaq Listing Rule 5635(c)(4).

The RSUs were granted on November 30, 2024, and represent an essential part of Karyopharm's approach to attracting and retaining talented professionals in the highly competitive pharmaceutical landscape. Each RSU will vest over a period of three years, with one-third of the shares becoming available to the employees on each of the three consecutive anniversaries from the grant date. However, the continuation of employment is a crucial factor for these shares to vest. If an employee's employment ends for 'good reason' or if Karyopharm terminates employment without cause within one year of a control change event, the RSUs will be immediately exercisable in full.

Karyopharm Therapeutics, listed on the Nasdaq under the ticker symbol KPTI, has been a pioneer in developing novel therapies aimed at treating various forms of cancer. Driven by a deep commitment to improving patient outcomes, Karyopharm has focused on the discovery and development of VXPO1, a first-in-class oral compound that inhibits nuclear export.

The flagship product, XPOVIO® (selinexor), has received regulatory approvals in the United States for several oncology indications and has also been marketed under the name NEXPOVIO® in the European Union and the United Kingdom, as well as other regions including China. The drug targets mechanisms that contribute to oncogenesis, providing therapeutic options for patients facing serious cancer diagnoses.

Karyopharm’s growing pipeline addresses numerous cancers with high unmet needs, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). This commitment not only highlights Karyopharm's innovative capabilities but also underscores the importance of retaining a dedicated workforce capable of advancing life-changing therapies.

As Karyopharm continues to expand its therapeutic offerings and solidify its position in the oncology space, the recent stock unit grants exemplify the company's efforts to bolster its team while adhering to regulatory compliance necessitated by its public listing.

For those interested in learning more about Karyopharm Therapeutics and its advancements in cancer therapies, further details can be found on their official website, as well as through their social media platforms including LinkedIn and X under the handle @Karyopharm.

In summary, Karyopharm's restricted stock unit grants portray a strategic initiative designed to attract and maintain skilled personnel, essential for the company's mission of delivering groundbreaking medical treatments to those battling cancer.